Biotech Hunter
Biotech Hunter
Home
Companies
Trials
People
Search
Clinical Trials Directory
Explore 21,535 clinical trials worldwide
Search
Showing 13301-13350 of 21,535 trials
Active filters:
Status: Active, not recruiting
Clinical Trials (21,535)
NCT04534959
Strategy to Avoid Excessive Oxygen for Critically Ill Trauma Patients
PHASE3
Active, not recruiting
6,000 participants
Started: Oct 15, 2020 · Completed: Jun 30, 2025
4 conditions
2 sponsors
8 locations
NCT04751864
Brain Stimulation & Generalized Anxiety Study
PHASE4
Active, not recruiting
150 participants
Started: Oct 15, 2020 · Completed: Jun 21, 2021
3 conditions
2 sponsors
1 location
NCT04524273
Myasthenia Gravis Inebilizumab Trial
PHASE3
Active, not recruiting
238 participants
Started: Oct 15, 2020 · Completed: Nov 29, 2027
1 condition
1 sponsor
104 locations
NCT03685331
HOPE: Olaparib, Palbociclib and Fulvestrant in Patients with BRCA Mutation-associated, HR+, HER2-metastatic Breast Cancer
PHASE1
Active, not recruiting
54 participants
Started: Oct 15, 2020 · Completed: Aug 31, 2025
5 conditions
1 sponsor
1 location
NCT04570579
Impact of a Novel Extended Depth of Focus Intraocular Lens on Visual and Lifestyle Enhancement
N/A
Active, not recruiting
46 participants
Started: Oct 14, 2020 · Completed: Dec 30, 2025
3 conditions
1 sponsor
1 location
NCT03859453
Follow-up in Early and Locally Advanced Breast Cancer Patients
N/A
Active, not recruiting
830 participants
Started: Oct 14, 2020 · Completed: Apr 30, 2024
1 condition
1 sponsor
28 locations
NCT04420975
Nivolumab and BO-112 Before Surgery for the Treatment of Resectable Soft Tissue Sarcoma
PHASE1
Active, not recruiting
14 participants
Started: Oct 14, 2020 · Completed: Jan 31, 2027
30 conditions
3 sponsors
1 location
NCT03868618
Dual-sided Hypoglossal neRvE stimulAtion for the treatMent of Obstructive Sleep Apnea (DREAM)
NA
Active, not recruiting
115 participants
Started: Oct 14, 2020 · Completed: Feb 29, 2028
1 condition
2 sponsors
21 locations
NCT04469556
Pancreatic Adenocarcinoma Signature Stratification for Treatment
PHASE2
Active, not recruiting
150 participants
Started: Oct 14, 2020 · Completed: Sep 30, 2026
3 conditions
7 sponsors
6 locations
NCT04202835
ATG Plus PTCy vs ATG for CGVHD Prophylaxis
PHASE2
Active, not recruiting
80 participants
Started: Oct 14, 2020 · Completed: Feb 7, 2026
3 conditions
4 sponsors
9 locations
NCT04599140
SX-682 and Nivolumab for the Treatment of RAS-Mutated, MSS Unresectable or Metastatic Colorectal Cancer, the STOPTRAFFIC-1 Trial
PHASE1/PHASE2
Active, not recruiting
51 participants
Started: Oct 14, 2020 · Completed: Jan 31, 2026
21 conditions
3 sponsors
1 location
NCT04580771
A Vaccine (PDS0101) and Chemoradiation for the Treatment of Stage IB3-IVA Cervical Cancer, the IMMUNOCERV Trial
PHASE2
Active, not recruiting
22 participants
Started: Oct 14, 2020 · Completed: Mar 8, 2027
14 conditions
2 sponsors
1 location
NCT04423939
ACT to Reduce Morbidity and Mortality in Hematopoietic Stem Cell Transplant (HCT) Patients
NA
Active, not recruiting
33 participants
Started: Oct 14, 2020 · Completed: Feb 17, 2025
1 condition
1 sponsor
1 location
NCT04221815
IMPact on Revascularization Outcomes of IVUS Guided Treatment of Complex Lesions and Economic Impact
NA
Active, not recruiting
3,100 participants
Started: Oct 14, 2020 · Completed: Sep 30, 2027
1 condition
1 sponsor
61 locations
NCT04440358
Exablate Blood-Brain Barrier Disruption With Carboplatin for the Treatment of rGBM
PHASE1/PHASE2
Active, not recruiting
13 participants
Started: Oct 13, 2020 · Completed: Jul 31, 2024
1 condition
1 sponsor
3 locations
NCT04155359
Clinical Evaluation of the miR Sentinel BCa™ Test to Diagnose Bladder Cancer in Hematuria Patients
N/A
Active, not recruiting
444 participants
Started: Oct 13, 2020 · Completed: Dec 31, 2024
1 condition
1 sponsor
1 location
NCT06074367
The Impact of Oral Vitamin C in Prevention for Post Operative Atrial Fibrillation (POAF) in Coronary Artery Bypass Surgery (CABG) Patients
PHASE4
Active, not recruiting
180 participants
Started: Oct 13, 2020 · Completed: Oct 30, 2023
1 condition
1 sponsor
1 location
NCT05524363
Assessment of Safety and Performances of HYPE SCS Stem Associated to NOVAE Sunfit TH Acetabular Cup in Hip Arthroplasty
N/A
Active, not recruiting
120 participants
Started: Oct 13, 2020 · Completed: Mar 1, 2027
1 condition
1 sponsor
1 location
NCT04284774
Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alterations, a Pediatric MATCH Treatment Trial
PHASE2
Active, not recruiting
5 participants
Started: Oct 13, 2020 · Completed: Sep 30, 2027
41 conditions
1 sponsor
172 locations
NCT05130580
Patient-Specific Decision Aid System for Shared Decision Making About Breast Reconstruction
NA
Active, not recruiting
35 participants
Started: Oct 13, 2020 · Completed: Feb 2, 2027
1 condition
3 sponsors
1 location
NCT04495153
CAN-2409 Plus Prodrug With Standard of Care Immune Checkpoint Inhibitor for Stage III/IV NSCLC
PHASE2
Active, not recruiting
90 participants
Started: Oct 13, 2020 · Completed: Dec 31, 2026
1 condition
2 sponsors
14 locations
NCT04538664
A Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy, Compared With Carboplatin-Pemetrexed, in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Characterized by Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions
PHASE3
Active, not recruiting
308 participants
Started: Oct 13, 2020 · Completed: Jan 31, 2026
1 condition
1 sponsor
229 locations
NCT04584710
A Phase 2 Study of RTB101 as COVID-19 Post-Exposure Prophylaxis in Older Adults
PHASE2
Active, not recruiting
60 participants
Started: Oct 13, 2020 · Completed: Feb 28, 2021
1 condition
2 sponsors
2 locations
NCT04535011
PRACT to Investigate Controlling Alcohol Related Harms in a Low-Income Setting; Emergency Department BIs in Tanzania
NA
Active, not recruiting
864 participants
Started: Oct 12, 2020 · Completed: Feb 28, 2027
3 conditions
3 sponsors
1 location
NCT04722575
Combination or Sequence of Vemurafenib, Cobimetinib, and Atezolizumab in High-risk, Resectable Melanoma
PHASE2
Active, not recruiting
95 participants
Started: Oct 12, 2020 · Completed: Jun 30, 2027
1 condition
2 sponsors
6 locations
NCT04531917
The Effect of Pain Neuroscience Education and Behavioural Graded Activity on Chronic Pain in Breast Cancer Survivors
NA
Active, not recruiting
122 participants
Started: Oct 12, 2020 · Completed: Dec 31, 2025
3 conditions
3 sponsors
1 location
NCT04446650
A Study of Fedratinib in Japanese Subjects With DIPSS (Dynamic International Prognostic Scoring System)- Intermediate or High-risk Primary Myelofibrosis (PMF), Post-polycythemia Vera Myelofibrosis (Post-PV MF), or Post-essential Thrombocythemia Myelofibrosis (Post-ET MF)
PHASE1/PHASE2
Active, not recruiting
31 participants
Started: Oct 12, 2020 · Completed: Nov 30, 2026
1 condition
1 sponsor
21 locations
NCT03993678
Intratumoral Injection of IP-001 Following Thermal Ablation in Patients With Advanced Solid Tumors.
PHASE1/PHASE2
Active, not recruiting
28 participants
Started: Oct 12, 2020 · Completed: Dec 31, 2025
1 condition
2 sponsors
3 locations
NCT04328350
Social Experiences of Adolescents and Young Adults With Cancer
N/A
Active, not recruiting
121 participants
Started: Oct 12, 2020 · Completed: Dec 31, 2026
3 conditions
1 sponsor
1 location
NCT04591405
Phase II/III of Live Attenuated Mumps (F-genotype) Vaccine (Human Diploid Cell, KMB-17) in Healthy Children Aged 5-11
PHASE2/PHASE3
Active, not recruiting
11,999 participants
Started: Oct 12, 2020 · Completed: Jul 1, 2024
1 condition
2 sponsors
1 location
NCT05242627
Firearm-Safety Counseling: Medical Student Training
NA
Active, not recruiting
360 participants
Started: Oct 11, 2020 · Completed: Dec 1, 2025
3 conditions
2 sponsors
1 location
NCT05129436
Adaptive Immune Response to Seasonal Influenza Vaccination (AIGI)
N/A
Active, not recruiting
20 participants
Started: Oct 10, 2020 · Completed: Dec 31, 2023
1 condition
1 sponsor
1 location
NCT04554940
A Clinical Trial to Evaluate Safety of Vosoritide in At-risk Infants With Achondroplasia
PHASE2
Active, not recruiting
20 participants
Started: Oct 10, 2020 · Completed: Dec 31, 2027
1 condition
1 sponsor
3 locations
NCT04393285
Abemaciclib and Letrozole to Treat Endometrial Cancer
PHASE2
Active, not recruiting
53 participants
Started: Oct 10, 2020 · Completed: Dec 1, 2025
1 condition
2 sponsors
29 locations
NCT04398745
A Study of Belantamab Mafodotin Monotherapy in Multiple Myeloma Participants With Normal and Varying Degree of Impaired Renal Function
PHASE1
Active, not recruiting
36 participants
Started: Oct 9, 2020 · Completed: Dec 31, 2025
1 condition
1 sponsor
19 locations
NCT04546009
A Study Evaluating the Efficacy and Safety of Giredestrant Combined With Palbociclib Compared With Letrozole Combined With Palbociclib in Participants With Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (persevERA Breast Cancer)
PHASE3
Active, not recruiting
992 participants
Started: Oct 9, 2020 · Completed: Mar 25, 2028
1 condition
1 sponsor
257 locations
NCT06717841
Metabolic Control and Glycemic Variability in Type 1 Diabetes and Celiac Disease
N/A
Active, not recruiting
200 participants
Started: Oct 9, 2020 · Completed: Dec 31, 2024
2 conditions
1 sponsor
1 location
NCT04451135
CET- REM (Correlating ECT Response to EEG Markers)
NA
Active, not recruiting
31 participants
Started: Oct 9, 2020 · Completed: Jun 30, 2027
2 conditions
1 sponsor
1 location
NCT04572295
A Study of E7090 as Monotherapy and in Combination With Other Anticancer Agents in Participants With Estrogen Receptor Positive (ER+) and Human Epidermal Growth Receptor 2 Negative (HER2-) Recurrent/Metastatic Breast Cancer
PHASE1
Active, not recruiting
51 participants
Started: Oct 9, 2020 · Completed: Mar 31, 2026
1 condition
1 sponsor
11 locations
NCT04513145
Adductor Canal Block
PHASE2/PHASE3
Active, not recruiting
130 participants
Started: Oct 9, 2020 · Completed: Dec 31, 2025
2 conditions
2 sponsors
1 location
NCT04549207
Comparing Continuation or De-escalation of Bone Modifying Agents (BMA) in Patients Treated for Over 2 Years for Bone Metastases From Either Breast or Castration-resistant Prostate Cancer
PHASE4
Active, not recruiting
240 participants
Started: Oct 9, 2020 · Completed: Jun 30, 2026
2 conditions
1 sponsor
5 locations
NCT04477603
Impella ECP Early Feasibility Study
NA
Active, not recruiting
100 participants
Started: Oct 9, 2020 · Completed: Oct 31, 2026
1 condition
1 sponsor
5 locations
NCT04419532
A Study Evaluating DS-1055a in Participants With Relapsed or Refractory Locally Advanced or Metastatic Solid Tumors
PHASE1
Active, not recruiting
40 participants
Started: Oct 9, 2020 · Completed: Jan 31, 2026
3 conditions
1 sponsor
6 locations
NCT04271358
Peer Coaching Intervention in Young Adults With Congenital Heart Disease
NA
Active, not recruiting
33 participants
Started: Oct 8, 2020 · Completed: Mar 2, 2032
2 conditions
2 sponsors
1 location
NCT04370483
Leflunomide for the Treatment of High-Risk Smoldering Multiple Myeloma
EARLY_PHASE1
Active, not recruiting
1 participants
Started: Oct 8, 2020 · Completed: Dec 16, 2025
1 condition
2 sponsors
1 location
NCT04434092
A Study Evaluating the Efficacy and Safety of Crovalimab Versus Eculizumab in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) Not Previously Treated With Complement Inhibitors
PHASE3
Active, not recruiting
204 participants
Started: Oct 8, 2020 · Completed: Sep 30, 2027
1 condition
2 sponsors
56 locations
NCT04529772
A Combination of Acalabrutinib With R-CHOP in Subjects With Previously Untreated Non-GCB DLBCL (ACE-LY-312)
PHASE3
Active, not recruiting
611 participants
Started: Oct 8, 2020 · Completed: Feb 1, 2027
1 condition
2 sponsors
255 locations
NCT04577261
FNS (FEMORAL NECK SYSTEM) Study
N/A
Active, not recruiting
50 participants
Started: Oct 7, 2020 · Completed: May 31, 2026
1 condition
1 sponsor
1 location
NCT04015622
PROstate Cancer TReatment Optimization Via Analysis of Circulating Tumour DNA
PHASE2
Active, not recruiting
100 participants
Started: Oct 7, 2020 · Completed: Dec 1, 2026
1 condition
1 sponsor
7 locations
NCT04540900
A Phase I Study of KB301, a Replication-Incompetent, Non-Integrating Vector Expressing Human Type III Collagen (COL3) for the Treatment of Superficial Skin Depressions
PHASE1
Active, not recruiting
85 participants
Started: Oct 7, 2020 · Completed: May 31, 2029
4 conditions
1 sponsor
4 locations
Previous
1
More pages
264
265
266
267
268
269
270
More pages
431
Next